<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38843198</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Assessing the association between antibody status and symptoms of long COVID: A multisite study.</ArticleTitle><Pagination><StartPage>e0304262</StartPage><MedlinePgn>e0304262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0304262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0304262</ELocationID><Abstract><AbstractText>The association between SARS-CoV-2 humoral immunity and post-acute sequelae of COVID-19 (long COVID) remains uncertain. The objective of this population-based cohort study was to assess the association between SARS-CoV-2 seropositivity and symptoms consistent with long COVID. English and Spanish-speaking members &#x2265; 18 years old with SARS-CoV-2 serologic testing conducted prior to August 2021 were recruited from Kaiser Permanente Southern California and Kaiser Permanente Colorado. Between November 2021 and April 2022, participants completed a survey assessing symptoms, physical health, mental health, and cognitive function consistent with long COVID. Survey results were linked to SARS-CoV-2 antibody (Ab) and viral (RNA) lab results in electronic health records. Weighted descriptive analyses were generated for five mutually exclusive patient groups: (1) +Ab/+RNA; (2) +Ab/- or missing RNA; (3) -Ab/+RNA; (4a) -Ab/-RNA reporting no prior infection; and (4b) -Ab/-RNA reporting prior infection. The proportions reporting symptoms between the +Ab/+RNA and -Ab/+RNA groups were compared, adjusted for covariates. Among 3,946 participants, the mean age was 52.1 years old (SD 15.6), 68.3% were female, 28.4% were Hispanic, and the serologic testing occurred a median of 15 months prior (IQR = 12-18). Three quarters (74.5%) reported having had COVID-19. Among people with laboratory-confirmed COVID-19, there was no association between antibody positivity (+Ab/+RNA vs. -Ab/+RNA) and any symptoms, physical health, mental health, or cognitive function. As expected, physical health, cognitive function, and fatigue were worse, and palpitations and headaches limiting the ability to work were more prevalent among people with laboratory-confirmed prior infection and positive serology (+Ab/+RNA) compared to those without reported or confirmed prior infection and negative serology (-Ab/-RNA/no reported COVID-19). Among people with laboratory-confirmed COVID-19, SARS-CoV-2 serology from practice settings were not associated with long COVID symptoms and health status suggesting limited utility of serology testing for long COVID.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Binswanger et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Binswanger</LastName><ForeName>Ingrid A</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0001-8862-8078</Identifier><AffiliationInfo><Affiliation>Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Colorado Permanente Medical Group, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bernard J. Tyson School of Medicine, Pasadena, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer-Toy</LastName><ForeName>Darryl E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood &amp; Chino Hills, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrow</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narwaney</LastName><ForeName>Komal J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruxvoort</LastName><ForeName>Katia J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Courtney R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Clinical Analysis at Southern California Permanente Medical Group, California, CA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glanz</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003120" MajorTopicYN="N" Type="Geographic">Colorado</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002140" MajorTopicYN="N" Type="Geographic">California</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>&#x201c;I have read the journal&#x2019;s policy and the authors of this manuscript have the following competing interests: Dr. Binswanger received royalties from UpToDate (Wolters Kluwer) for unrelated educational content on the health of incarcerated persons. Dr. Bruxvoort has received funding from Moderna, Pfizer, Dynavax, Gilead, and GlaxoSmithKline for unrelated research. This commercial funding does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>19</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38843198</ArticleId><ArticleId IdType="pmc">PMC11156415</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0304262</ArticleId><ArticleId IdType="pii">PONE-D-23-27551</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mirin AA. A preliminary estimate of the economic impact of long COVID in the United States. Fatigue: Biomedicine, Health &amp; Behavior. 2022;10(4):190&#x2013;9.</Citation></Reference><Reference><Citation>Smith N DM, Wong G, Conte T, Lakzadeh P, Bunka M, Ceka A, et al.. COVID-19 living evidence synthesis #11.1: Socioeconomic impact of post COVID-19 condition: Final report. Vancouver, Canada: Centre for Clinical Epidemiology and Evaluation; 2023. January 31.</Citation></Reference><Reference><Citation>Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, et al.. Long COVID through a public health lens: An umbrella review. Public Health Rev. 2022;43:1604501. doi: 10.3389/phrs.2022.1604501</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/phrs.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, et al.. Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022. Clin Infect Dis. 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10425195</ArticleId><ArticleId IdType="pubmed">37074868</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, et al.. Population immunity to pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 variants in US states and counties through 1 December 2021. Clin Infect Dis. 2023;76(3):e350&#x2013;e9. doi: 10.1093/cid/ciac438</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac438</ArticleId><ArticleId IdType="pmc">PMC9214178</ArticleId><ArticleId IdType="pubmed">35717642</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;46. doi: 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al.. Post&#x2013;COVID Conditions Among Adult COVID-19 Survivors Aged 18&#x2013;64 and &#x2265;65 Years&#x2014;United States, March 2020&#x2013;November 2021. MMWR. 2022;71(21):713&#x2013;7.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;15. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H, Assaf G, McCorkell L, Wei H, Low R, Re&#x2019;em Y, et al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Post COVID-19 condition (long COVID)
2022.  [updated December 7, 2022; cited 2023 March 15]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services. About long COVID. 2023. December 4.</Citation></Reference><Reference><Citation>Salmon-Ceron D, Slama D, De Broucker T, Karmochkine M, Pavie J, Sorbets E, et al.. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study. J Infect. 2021;82(2):e1&#x2013;e4. doi: 10.1016/j.jinf.2020.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7833274</ArticleId><ArticleId IdType="pubmed">33285216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al.. Persistent symptoms after Covid-19: Qualitative study of 114 "long COVID" patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1144. doi: 10.1186/s12913-020-06001-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-06001-y</ArticleId><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al.. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers
2022.  [updated December 16, 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html.</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research I. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;61. doi: 10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskett WI, Qureshi AI, Shyu D, Armer JM, Shyu CR. COVID-specific long-term sequelae in comparison to common viral respiratory infections: An analysis of 17 487 infected adult patients. Open Forum Infect Dis. 2023;10(1):ofac683. doi: 10.1093/ofid/ofac683</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac683</ArticleId><ArticleId IdType="pmc">PMC9846186</ArticleId><ArticleId IdType="pubmed">36686632</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al.. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open. 2021;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, et al.. Symptom burden and immune dynamics 6 to 18 months following mild severe acute respiratory syndrome Coronavirus 2 infection (SARS-CoV-2): A case-control study. Clin Infect Dis. 2023;76(3):e60&#x2013;e70. doi: 10.1093/cid/ciac655</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac655</ArticleId><ArticleId IdType="pmc">PMC9384725</ArticleId><ArticleId IdType="pubmed">35959897</ArticleId></ArticleIdList></Reference><Reference><Citation>Horberg MA, Watson E, Bhatia M, Jefferson C, Certa JM, Kim S, et al.. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat Commun. 2022;13(1):5822. doi: 10.1038/s41467-022-33573-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33573-6</ArticleId><ArticleId IdType="pmc">PMC9556630</ArticleId><ArticleId IdType="pubmed">36224218</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, Liang CJ, Marques AR, Chung JY, Shanbhag SM, Fontana JR, et al.. A longitudinal study of COVID-19 sequelae and immunity: Baseline findings. Ann Intern Med. 2022;175(7):969&#x2013;79. doi: 10.7326/M21-4905</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4905</ArticleId><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al.. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446. doi: 10.1038/s41467-021-27797-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing
2022.  [updated December 16, 2022; cited 2023 January 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html.</Citation></Reference><Reference><Citation>Hanson KE, Caliendo AM, Arias CA, Englund JA, Hayden MK, Lee MJ, et al.. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing. Clin Infect Dis. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543294</ArticleId><ArticleId IdType="pubmed">32918466</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, Garcia JA, Agullo V, Andreo M, et al.. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: A longitudinal study. J Clin Immunol. 2021;41(7):1490&#x2013;501. doi: 10.1007/s10875-021-01083-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome? Mol Neurobiol. 2022;59(3):1850&#x2013;61. doi: 10.1007/s12035-021-02696-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Varnai R, Molnar T, Zavori L, Tokes-Fuzesi M, Illes Z, Kanizsai A, et al.. Serum level of anti-nucleocapsid, but not anti-spike antibody, is associated with improvement of long COVID symptoms. Vaccines (Basel). 2022;10(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924883</ArticleId><ArticleId IdType="pubmed">35214624</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorado Department of Public Health and Environment. Colorado&#x2019;s COVID-19 Data
2022.  [cited 2022 November 15]. Available from: https://covid19.colorado.gov/data.</Citation></Reference><Reference><Citation>Bruxvoort KJ, Shi J, Song H, Narwaney K, Glanz JM, Binswanger I, et al.. SARS-CoV-2 serology did not predict risk of breakthrough infection during the Omicron BA.1 and BA.2 surge. Arch Pathol Lab Med. 2024;148(1):7&#x2013;11. doi: 10.5858/arpa.2023-0311-LE</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2023-0311-LE</ArticleId><ArticleId IdType="pubmed">37796481</ArticleId></ArticleIdList></Reference><Reference><Citation>Binswanger IA, Narwaney KJ, Barrow JC, Albers KB, Bechtel L, Steiner CA, et al.. Association between severe acute respiratory syndrome coronavirus 2 antibody status and reinfection: A case-control study nested in a Colorado-based prospective cohort study. Prev Med Rep. 2024;37:102530. doi: 10.1016/j.pmedr.2023.102530</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2023.102530</ArticleId><ArticleId IdType="pmc">PMC10776776</ArticleId><ArticleId IdType="pubmed">38205171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al.. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020;58(8). doi: 10.1128/JCM.00941-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00941-20</ArticleId><ArticleId IdType="pmc">PMC7383515</ArticleId><ArticleId IdType="pubmed">32381641</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott Laboratories Diagnostics Division. SARS-CoV-2 IgG. 2020 5/26/2020.</Citation></Reference><Reference><Citation>Withers KL, Wood KA, Carolan-Rees G, Patrick H, Lencioni M, Griffith M. Establishing content validity in a novel patient reported outcome measure for cardiac arrhythmia ablation patients. Health Qual Life Outcomes. 2015;13:38. doi: 10.1186/s12955-015-0233-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-015-0233-5</ArticleId><ArticleId IdType="pmc">PMC4520263</ArticleId><ArticleId IdType="pubmed">25884567</ArticleId></ArticleIdList></Reference><Reference><Citation>Northwestern University. HealthMeasures: Transforming How Health is Measured
2023.  [updated March 7, 2023; cited 2021 August 15]. Available from: https://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis/list-of-adult-measures.</Citation></Reference><Reference><Citation>Mattos A, Souza JA, Moreira PFF, Jurno ME, Velarde LGC. ID-Migraine questionnaire and accurate diagnosis of migraine. Arq Neuropsiquiatr. 2017;75(7):446&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">28746431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the Seattle angina questionnaire. Circ Cardiovasc Qual Outcomes. 2014;7(5):640&#x2013;7. doi: 10.1161/CIRCOUTCOMES.114.000967</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.114.000967</ArticleId><ArticleId IdType="pmc">PMC4282595</ArticleId><ArticleId IdType="pubmed">25185249</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson&#x2019;s disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306&#x2013;12. doi: 10.1002/mds.20153</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20153</ArticleId><ArticleId IdType="pubmed">15390007</ArticleId></ArticleIdList></Reference><Reference><Citation>Athena Akrami P.
Online Survey on Recovery from COVID-19
2021.  [Available from: https://patientresearchcovid19.com/survey2/.</Citation></Reference><Reference><Citation>Gupta M, Mysore V. Classifications of patterned hair loss: A review. J Cutan Aesthet Surg. 2016;9(1):3&#x2013;12. doi: 10.4103/0974-2077.178536</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0974-2077.178536</ArticleId><ArticleId IdType="pmc">PMC4812885</ArticleId><ArticleId IdType="pubmed">27081243</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Veterans Affairs. Alcohol Use Disorders Identification Test
2019.  [updated September 11, 2019. Available from: https://www.hepatitis.va.gov/alcohol/treatment/audit-c.asp#:~:text=The%20AUDIT-C%20is%20scored,his%2Fher%20health%20and%20safety.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. National Health Interview Survey
2019.  [updated 2019; cited 2021 September 15]. Available from: https://www.cdc.gov/nchs/nhis/2019nhis.htm.</Citation></Reference><Reference><Citation>Pearson JL, Hitchman SC, Brose LS, Bauld L, Glasser AM, Villanti AC, et al.. Recommended core items to assess e-cigarette use in population-based surveys. Tob Control. 2018;27(3):341&#x2013;6. doi: 10.1136/tobaccocontrol-2016-053541</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tobaccocontrol-2016-053541</ArticleId><ArticleId IdType="pmc">PMC6934252</ArticleId><ArticleId IdType="pubmed">28624764</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O&#x2019;Neal L, et al.. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bichara CDA, da Silva Graca Amoras E, Vaz GL, da Silva Torres MK, Queiroz MAF, do Amaral IPC, et al.. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population. BMC Infect Dis. 2021;21(1):443. doi: 10.1186/s12879-021-06156-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06156-x</ArticleId><ArticleId IdType="pmc">PMC8122196</ArticleId><ArticleId IdType="pubmed">33992073</ArticleId></ArticleIdList></Reference><Reference><Citation>Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Wanlapakorn N, Sudhinaraset N, et al.. Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Sci Rep. 2021;11(1):23216. doi: 10.1038/s41598-021-02659-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02659-4</ArticleId><ArticleId IdType="pmc">PMC8636620</ArticleId><ArticleId IdType="pubmed">34853374</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al.. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130&#x2013;9. doi: 10.1097/01.mlr.0000182534.19832.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mlr.0000182534.19832.83</ArticleId><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al.. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares SR, da Silva Torres MK, Lima SS, de Sarges KML, Santos EFD, de Brito M, et al.. Antibody response to the SARS-CoV-2 spike and nucleacapsid proteins in patients with different COVID-19 clinical profiles. Viruses. 2023;15(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10141342</ArticleId><ArticleId IdType="pubmed">37112878</ArticleId></ArticleIdList></Reference><Reference><Citation>de Erausquin GA, Snyder H, Carrillo M, Hosseini AA, Brugha TS, Seshadri S, Consortium CS-C-. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17(6):1056&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10431934</ArticleId><ArticleId IdType="pubmed">33399270</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al.. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023. doi: 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Ghosh AK, Nyman MA, Croghan IT, Grach SL, Anstine CV, et al.. PROMIS scales for assessment of persistent post-COVID symptoms: A cross sectional study. J Prim Care Community Health. 2021;12:21501327211030413. doi: 10.1177/21501327211030413</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501327211030413</ArticleId><ArticleId IdType="pmc">PMC8267017</ArticleId><ArticleId IdType="pubmed">34231395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, et al.. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil. 2022;101(1):48&#x2013;52. doi: 10.1097/PHM.0000000000001910</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisk LE, Nichol G, Elmore JG. Toward unbiased evaluation of postacute sequelae of SARS-CoV-2 infection: Challenges and solutions for the long haul ahead. Ann Intern Med. 2022;175(5):740&#x2013;3. doi: 10.7326/M21-4664</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4664</ArticleId><ArticleId IdType="pmc">PMC8906529</ArticleId><ArticleId IdType="pubmed">35254883</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>